MannKind (NASDAQ:MNKD – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare MannKind to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Profitability
This table compares MannKind and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MannKind | -18.10% | N/A | -10.01% |
| MannKind Competitors | -12,519.20% | -215.47% | -31.42% |
Analyst Ratings
This is a summary of recent recommendations and price targets for MannKind and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MannKind | 1 | 2 | 7 | 0 | 2.60 |
| MannKind Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
MannKind currently has a consensus target price of $8.50, suggesting a potential upside of 121.07%. As a group, “Biotechnology” companies have a potential upside of 114.70%. Given MannKind’s stronger consensus rating and higher probable upside, equities research analysts plainly believe MannKind is more favorable than its competitors.
Risk & Volatility
MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, MannKind’s competitors have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Earnings and Valuation
This table compares MannKind and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MannKind | $348.97 million | $5.86 million | -16.72 |
| MannKind Competitors | $751.08 million | $10.42 million | -17.98 |
MannKind’s competitors have higher revenue and earnings than MannKind. MannKind is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
49.5% of MannKind shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
MannKind beats its competitors on 9 of the 13 factors compared.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
